|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.V. Komyakhov, A.S. Emelyanov, A.O. Gorina
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
|
№14 / 2023
|
|
M.A. Dzhelyalova, V.F. Semiglazov
Ways to improve endocrine therapy in postmenopausal women with ER+/HER2- breast cancer
|
№11 / 2021
|
|
M.A. Dzhelyalova, V.F. Semiglazov
Endocrine resistance in breast cancer treatment
|
№11 / 2020
|
|
T.Yu. Semiglazova (1, 2), I.V. Sorokina (3)
Prognostic and predictive values of the PIK3CA gene mutation in patients with breast cancer
|
№7 / 2019
|
|
D.D. Sakaeva, A.I. Iskhakova, R.I. Kunafina
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
|
№7 / 2018
|
|
L.G. Zhukova, E.I. Chichikov, O.O. Gordeeva, D.A. Filonenko
PALBOCICLIB – NEW POSSIBILITIES OF THERAPY OF HORMON-POSITIVE HER2-NEGATIVE BREAST CANCER
|
№17 / 2017
|
|
L.G. Zhukova, A.G. Manikhas
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
|
№17 / 2016
|
|
E.I. Borisova, G.V. Vyshinskaya, S.L. Gutorov, M.V. Stepanchenko
CLINICAL FEATURES OF INVASIVE LOBULAR BREAST CANCER
|
№17 / 2014
|
|
E.I. Borisova 1, S.L. Gutorov 1, A.Yu. Vorontsov 2
Hormonal Treatment Of Breast Cancer: Optimal Sequence And Issues Of Overcoming The Resistance
|
№18 / 2012
|
|
G.A. Dashian, V.F. Semiglazov, V.V. Semiglazov, N.Sh. Migmanova, O.A. T.T. Tabagua, A.G. Vasilyev
Breast Cancer And Pregnancy
|
№18 / 2009
|
Русский
